Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UKB1

UPID:
FBW1B_HUMAN

ALTERNATIVE NAMES:
F-box and WD repeats protein beta-TrCP2; F-box/WD repeat-containing protein 1B; Homologous to Slimb protein

ALTERNATIVE UPACC:
Q9UKB1; B2RC98; Q9P2S8; Q9P2S9; Q9Y4C6

BACKGROUND:
The protein FBXW11, known for its substrate recognition component in the SCF E3 ubiquitin-protein ligase complex, is essential for the ubiquitination of phosphorylated proteins, playing a key role in various cellular mechanisms including Wnt signaling, NF-kappa-B activation, and cell cycle regulation.

THERAPEUTIC SIGNIFICANCE:
Given FBXW11's critical role in Neurodevelopmental, jaw, eye, and digital syndrome, exploring its functions further could lead to innovative therapeutic approaches for managing this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.